The Top 5 Biosimilar Articles for the Week of October 25
Here are the top 5 biosimilar articles for the week of October 25, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of October 25, 2021.
Number 5: Competitors in the field of adalimumab and insulin products may soon include “authorized biologics” in addition to biosimilars and interchangeable biosimilars, a pharmacy expert explained at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021 meeting.
Number 4: Pharmacists have limited awareness of concepts underlying FDA approval of the interchangeable designation for biosimilars, according to survey findings presented at the AMCP Nexus 2021 meeting.
Number 3: Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the AMCP 2021 Nexus meeting.
Number 2: Year-over-year biosimilar revenues climbed 10% at Biocon Biologics amid a general reduction in income, the company said in an earnings statement.
Number 1: Hopes that insulin biosimilars can improve access and affordability will be tested by Express Scripts’ plan to give preferred formulary status to Semglee, a long-acting insulin that is interchangeable with Lantus.
To read all of these articles and more, visit centerforbiosimilars.com.
